Clinical effects of far-infrared therapy in patients with allergic rhinitis
Ko-Hsin Hu 1, Wen-Tyng Li
1Department of Biomedical Engineering, Chung-Yuan Christian University, Chung-Li, 32023 Taiwan, ROC. email@example.com
PMID: 18002246 DOI: 10.1109/IEMBS.2007.4352580
過敏性鼻炎（AR）是全球第六大常見慢性疾病，對患者的生活質量有重大影響。AR的實際成本驚人，每年直接醫療費用和其他間接費用約花費56億美元。因此，應認真對其進行評估和治療。AR是IgE介導的炎症，其症狀可能是由於血管通透性增加引起的。目前的治療選項，如避免過敏原、藥物和免疫療法都不令人滿意。遠紅外線（FIR）是一種不可見的電磁波，波長比可見光長。由於血流增加，它已被用於治療血管疾病。本研究的目的是評估FIR治療對AR患者的臨床效果。本研究共招募了31名AR患者。將WS TY101 FIR發射器放置在距患者鼻部區域30厘米的地方。治療每天早上進行40分鐘，持續7天。每天，患者在治療前和治療期間都在日記中記錄他們的症狀。根據嚴重程度，鼻炎的每個症狀都按4分制（0-3）評分。在FIR治療期間，眼睛癢、鼻子癢、鼻塞、流鼻涕和打噴嚏的症狀都有明顯改善。直到最後一次治療後，嗅覺障礙才得到改善。在治療和隨訪期間，患者未觀察到明顯不良反應。我們得出結論，FIR治療可以改善AR的症狀，可能成為AR的新型治療方式。
Allergic rhinitis (AR) is the sixth most common chronic illness worldwide, which has a significant impact on patients’ quality of life. The actual cost of AR is staggering, approximately $5.6 billion being spent annually in direct medical costs and other indirect costs. Therefore, it should be taken seriously upon its evaluation and treatment. AR is an IgE-mediated inflammation, which symptoms are likely due to increased vascular permeability. Current therapeutic options such as avoidance of allergen, medication and immunotherapy are unsatisfactory. Far-infrared (FIR) is an invisible electromagnetic wave with a wavelength longer than that of visible light. It has been used to treat vascular diseases as a result of an increase in blood flow. The objective of this study was to evaluate the clinical effects of FIR therapy in patients with AR. Thirty-one patients with AR were enrolled in this study. A WS TY101 FIR emitter was placed to face the patient’s nasal region at a distance of 30 cm. The treatment was performed for 40 min every morning for 7 days. Every day, patients recorded their symptoms in a diary before and during treatment. Each symptom of rhinitis was rated on a 4-point scale (0-3) according to severity. During the period of FIR therapy, the symptoms of eye itching, nasal itching, nasal stuffiness, rhinorrhea and sneezing were all significantly improved. Smell impairment was not improved until after the last treatment. No obvious adverse effect was observed in the patients during treatment and follow-up. We concluded that FIR therapy could improve the symptoms of AR and might serve as a novel treatment modality for AR.